Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.
Journal Information
Full Title: Oncol Lett
Abbreviation: Oncol Lett
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Competing interests MK declares conference fees for Pfizer, Roche, Novartis, Teva, and Amgen; clinical trials for Roche, MSD, Novartis, Seagen, and Gilead; speaker's honoraria from Novartis, Roche, Lilly, Teva, and Amgen, Swixx Biopharma; advisory board for Novartis; all outside the submitted work. MJ declares conference fees for Gilead, Roche; clinical trials for Roche, MSD, Novartis, Seagen, and Gilead; speaker's honoraria from Novartis, Roche, Lilly, Pfizer, Teva, Exact Sciences, and Mammotome; advisory boards for Novartis and Pfizer; all outside submitted work. All other authors declare they have no competing interests."
"The present study was supported by the National Science Centre, Poland (grant no. 2021/05/X/NZ5/00971)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025